Quotidian Technical Highlights on Selected Drug Makers Stocks -- TherapeuticsMD, Impax Laboratories, GlaxoSmithKline, and AstraZeneca

Friday, December 29, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, December 29, 2017 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment

community.  Today we are offering reports on TXMD, IPXL, GSK, and AZN which can be accessed for free by signing up to www.wallstequities.com/registration. Today's focus is shifted on the Drug Manufacturers space, which comprises companies that develop
and sell medicines and vaccines for a wide range of medical uses. Many of these companies offer slightly higher-than-average dividend yields. Today, WallStEquities.com tracks the performance of four major players in this industry: TherapeuticsMD Inc. (NASDAQ: TXMD), Impax Laboratories Inc. (NASDAQ: IPXL), GlaxoSmithKline PLC (NYSE: GSK), and AstraZeneca PLC (NYSE: AZN). All you have to do is sign up today for this free limited time offer, click the link below.

www.wallstequities.com/registration

TherapeuticsMD

On Thursday, shares in Boca Raton, Florida headquartered TherapeuticsMD Inc. recorded a trading volume of 1.67 million shares. The stock ended at $5.93, rising 1.19% from the last trading session. The Company's shares have gained 15.82% over the previous three months and 2.77% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.21% and 7.04%, respectively. Furthermore, shares of TherapeuticsMD, which operates as a women's health care product company, have a Relative Strength Index (RSI) of 48.73. 

On December 19th, 2017, TherapeuticsMD announced the acceptance of the New Drug Application resubmission for TX-004HR, the Company's investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy due to menopause, by the US FDA. The Prescription Drug User Fee Act target action date for the completion of the FDA's review is May 29th, 2018. Get the full research report on TXMD for free by clicking below at:

www.wallstequities.com/registration/?symbol=TXMD

Impax Laboratories

Hayward, California headquartered Impax Laboratories Inc.'s stock finished yesterday's session 0.30% higher at $16.90 with a total trading volume of 641,819 shares. The Company's shares have gained 5.62% in the last one month and 27.55% on an YTD basis. The stock is trading slightly below its 200-day moving average by 0.40%. Furthermore, shares of Impax Labs, which develops, manufactures, and markets bioequivalent pharmaceutical products, have an RSI of 44.50. 

On December 12th, 2017, research firm Guggenheim initiated a 'Neutral' rating on the Company's stock, with a target price of $18 per share.

On December 19th, 2017, Impax Labs (IPXL) announced that it has entered into a definitive agreement to sell its manufacturing facility in Taiwan to Bora Pharmaceuticals Co, Ltd. This sale supports IPXL's operational and cost improvement plans to streamline operations and reduce costs. IPXL expects to record a pre-tax impairment charge of approximately $70.0 to $80.0 million in Q4 of this year as a result of the sale.  The free technical report on IPXL can be accessed at:

www.wallstequities.com/registration/?symbol=IPXL

GlaxoSmithKline

At the close of trading on Thursday, shares in Brentford, the UK headquartered GlaxoSmithKline PLC saw a slight decline of 0.17%, ending the day at $35.50. The stock recorded a trading volume of 4.81 million shares. The Company's shares are trading 1.83% below their 50-day moving average. Moreover, shares of GlaxoSmithKline have an RSI of 50.49. 

On December 12th, 2017, GlaxoSmithKline announced that the US FDA has approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis, previously known as Churg-Strauss syndrome. The Company submitted a supplemental Biologics License Application for mepolizumab, an interleukin-5 antagonist, in June 2017. Sign up for free on Wall St. Equities and claim the latest report on GSK at:

www.wallstequities.com/registration/?symbol=GSK

AstraZeneca

Cambridge, the UK headquartered AstraZeneca PLC's shares ended the day 1.16% higher at $34.11 with a total trading volume of 2.44 million shares. The stock has gained 1.76% in the last month, 1.88% over the previous three months, and 24.85% on an YTD basis. The Company's shares are trading 1.73% above their 50-day moving average and 4.87% above their 200-day moving average. Additionally, shares of AstraZeneca, which discovers, develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide, have an RSI of 62.50. 

On December 21st, 2017, AstraZeneca announced that the US FDA has approved updates to the SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol labeling, including removal of the Boxed WARNING for serious asthma-related outcomes. SYMBICORT is a combination formulation containing budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic agonist bronchodilator in a single inhaler. See the free research coverage on AZN at:

www.wallstequities.com/registration/?symbol=AZN

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACTFor any questions, inquiries, or comments reach out to us directly.If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-drug-makers-stocks----therapeuticsmd-impax-laboratories-glaxosmithkline-and-astrazeneca-300576040.html

SOURCE Wall St. Equities

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store